OpenAI researcher Miles Wang is in discussions to launch a new AI drug discovery startup, potentially valued at $2 billion, with plans to raise around $200 million in funding. This venture aims to leverage AI for breakthroughs in life sciences, particularly in finding new uses for existing drugs, and is expected to attract other researchers from OpenAI.
Miles Wang, a former OpenAI researcher, is planning to launch an AI drug discovery startup with a significant $2 billion valuation and a potential $200 million funding round led by Lightspeed. This indicates strong investor interest in AI applications for life sciences, particularly in models that can repurpose existing FDA-approved drugs, providing faster revenue opportunities compared to developing new drugs. This development may signal a valuable opportunity for investment or partnership in the rapidly growing AI-driven drug discovery market.